Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Queensland Health
UBS
Chubb
Novartis
Express Scripts
Johnson and Johnson
Fuji
Medtronic
Moodys

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090445

« Back to Dashboard
NDA 090445 describes NABUMETONE, which is a drug marketed by Chartwell Molecules, Mylan Pharms Inc, Dr Reddys Labs Ltd, Apotex Inc, Lupin Ltd, Invagen Pharms, Copley Pharm, Sandoz, Watson Labs, Impax Labs Inc, and Oxford Pharms, and is included in twelve NDAs. It is available from forty-two suppliers. Additional details are available on the NABUMETONE profile page.

The generic ingredient in NABUMETONE is nabumetone. There are twenty drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the nabumetone profile page.

Summary for NDA: 090445

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 090445

Suppliers and Packaging for NDA: 090445

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NABUMETONE
nabumetone
TABLET;ORAL 090445 ANDA Lupin Pharmaceuticals, Inc. 68180-141 68180-141-01 100 TABLET, FILM COATED in 1 BOTTLE (68180-141-01)
NABUMETONE
nabumetone
TABLET;ORAL 090445 ANDA Lupin Pharmaceuticals, Inc. 68180-141 68180-141-03 1000 TABLET, FILM COATED in 1 BOTTLE (68180-141-03)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG
Approval Date:Jan 12, 2011TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength750MG
Approval Date:Jan 12, 2011TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
McKinsey
Boehringer Ingelheim
Moodys
Julphar
Deloitte
QuintilesIMS
Baxter
Citi
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot